Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CUR
Previous Symbol
CUSIPN/A
Phone301-366-4841
Debt
Debt-to-Equity RatioN/A
Current Ratio10.41
Quick Ratio10.41
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$260,000.00
Price / Sales31.49
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book0.96
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-15,660,000.00
Net Margins-1,401.80%
Return on Equity-75.90%
Return on Assets-48.98%
Miscellaneous
Employees6
Outstanding Shares15,160,000
Market Cap$7.73 million
OptionableOptionable
Neuralstem (NASDAQ:CUR) Frequently Asked Questions
What is Neuralstem's stock symbol?
Neuralstem trades on the NASDAQ under the ticker symbol "CUR."
How were Neuralstem's earnings last quarter?
Neuralstem, Inc. (NASDAQ:CUR) released its quarterly earnings data on Wednesday, November, 14th. The company reported ($0.12) earnings per share (EPS) for the quarter. Neuralstem had a negative net margin of 1,401.80% and a negative return on equity of 75.90%. View Neuralstem's Earnings History.
When is Neuralstem's next earnings date?
What price target have analysts set for CUR?
0 brokerages have issued 12-month price objectives for Neuralstem's shares. Their forecasts range from $1.91 to $1.91. On average, they anticipate Neuralstem's stock price to reach $1.91 in the next year. This suggests a possible upside of 253.7% from the stock's current price. View Analyst Price Targets for Neuralstem.
Has Neuralstem been receiving favorable news coverage?
News coverage about CUR stock has trended neutral this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Neuralstem earned a news impact score of 0.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of Neuralstem's key competitors?
Some companies that are related to Neuralstem include Vical (VICL), CytRx (CYTR), Genetic Technologies (GENE), Mymetics (MYMX), TrovaGene (TROV), Vaxart (VXRT), Arsanis (ASNS), aTyr Pharma (LIFE), Microbot Medical (MBOT), Windtree Therapeutics (WINT), Enzon Pharmaceuticals (ENZN), Titan Pharmaceuticals (TTNP), Mateon Therapeutics (MATN), Vitro Diagnostics (VODG) and Taxus Cardium Pharmaceuticals Group (CRXM).
Who are Neuralstem's key executives?
Neuralstem's management team includes the folowing people:
- Mr. James B. Scully, Interim CEO & Principal Accounting Officer (Age 56)
- Dr. Karl Y. Johe Ph.D., Co-Founder & Chief Scientific Officer (Age 58)
- Dr. Thomas G. Hazel Ph.D., Sr. VP of Research
- Dr. David P. Recker, Chief Medical Officer (Age 60)
How do I buy shares of Neuralstem?
Shares of CUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neuralstem's stock price today?
One share of CUR stock can currently be purchased for approximately $0.54.
How big of a company is Neuralstem?
Neuralstem has a market capitalization of $7.73 million and generates $260,000.00 in revenue each year. Neuralstem employs 6 workers across the globe.
What is Neuralstem's official website?
How can I contact Neuralstem?
Neuralstem's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 301-366-4841 or via email at [email protected]
MarketBeat Community Rating for Neuralstem (NASDAQ CUR)
MarketBeat's community ratings are surveys of what our community members think about Neuralstem and other stocks. Vote "Outperform" if you believe CUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUR will underperform the S&P 500 over the long term. You may vote once every thirty days.
